You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
WAY 161503 hydrochloride
Potent and selective 5-HT2C receptor agonist (Ki = 4 nM; EC50 = 12 nM). Antidepressant following systemic administration in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Cryan and Lucki (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J.Pharmacol.Exp.Ther. 295 1120 PMID: 11082448
Welmaker et al (2000) Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg.Med.Chem.Lett. 10 1991 PMID: 10987434
Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211 PMID: 23301527
If you know of a relevant reference for WAY 161503 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: WAY 161503 hydrochloride, WAY 161503 hydrochloride supplier, Potent, selective, 5-HT2C, agonists, Serotonin, Receptors, WAY161503, hydrochloride, 1801, Tocris Bioscience
4 Citations for WAY 161503 hydrochloride
Citations are publications that use Tocris products. Selected citations for WAY 161503 hydrochloride include:
Hirono (2017) Monoaminergic modulation of GABAergic transmission onto cerebellar globular cells. Neuropharmacology 118 79 PMID: 28300552
Doslikova et al (2013) 5-HT2C receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated. J Neurosci 33 9800 PMID: 23739976
Banas et al (2011) Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology 36 423 PMID: 20927048
Mbaki (2008) Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat. Br J Pharmacol 155 343 PMID: 18604238
Do you know of a great paper that uses WAY 161503 hydrochloride from Tocris? Please let us know.
Reviews for WAY 161503 hydrochloride
There are currently no reviews for this product. Be the first to review WAY 161503 hydrochloride and earn rewards!
Have you used WAY 161503 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.